Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Loop diuretics - translating pharmacokinetic properties into improved clinical outcomes
Autore:
Brater, DC;
Indirizzi:
Indiana Univ, Sch Med, Indianapolis, IN 46202 USA Indiana Univ Indianapolis IN USA 46202 ch Med, Indianapolis, IN 46202 USA
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: G, volume: 3, anno: 2001,
pagine: G19 - G24
SICI:
1520-765X(200107)3:G<G19:LD-TPP>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONGESTIVE-HEART-FAILURE; FUROSEMIDE; BIOAVAILABILITY; PHARMACODYNAMICS; ABSORPTION; TORASEMIDE; TORSEMIDE; HEALTH; FOOD;
Keywords:
heart failure; torsemide; furosemide; absorption; clinical outcome; hospitalizations;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Brater, DC Indiana Univ, Sch Med, Fesler Hall 302,1120 South Dr, Indianapolis, IN 46202 USA Indiana Univ Fesler Hall 302,1120 South Dr Indianapolis IN USA 46202
Citazione:
D.C. Brater, "Loop diuretics - translating pharmacokinetic properties into improved clinical outcomes", EUR H J SUP, 3(G), 2001, pp. G19-G24

Abstract

Furosemide and torasemide have the same mechanism of action. However, theydiffer substantially in their pharmacokinetic properties. Furosemide is incompletely absorbed with substantial inter- and intra-individual variability. This contrasts with the complete and predictable absorption of torasemide. Theoretically, incomplete absorption could result in sodium accumulationthat over time would cause cardiac decompensation in patients with congestive heart failure (CHF). Several studies have addressed this issue: two retrospective analyses, one pre/post-comparison and one randomized clinical trial consistently showed that heart failure patients treated with torasemidehad fewer hospital admissions due to worsening heart failure or due to allcardiovascular causes. Moreover, functional state improved in comparison with furosemide in equipotent doses. In the two prospective trials there wasalso a decrease in cardiovascular and/or total mortality in comparison with furosemide, although this was not significant; the studies were not powered to show this. Most recently, a prospective cohort study that followed 2303 patients randomized in a 1:1 ratio to either torasemide or furosemide treatment for 1 year showed significantly fewer symptoms in the torasemide group and a significant decrease in cardiac as well as total mortality. Overall these data indicate that the complete and predictable absorption of torasemide extrapolates to improved clinical outcome in patients with CHF. (Eur Heart J Supplements 2001; 3 (Suppl G): G19-G24) (C) 2001 The European Society of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 21:47:33